FdaApplication
NDA 216340
Identifiers
- fda_app_no: NDA216340
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2022-12-12 |
Revenue by product
KRAZATI
| Period | Revenue |
|---|---|
| Q2 2026 | $55.0M |
| Q1 2026 | $50.0M |
| Q4 2025 | $56.0M |
| Q3 2025 | $53.0M |
| Q2 2025 | $48.0M |
| Q1 2025 | $48.0M |
| Q4 2024 | $39.0M |
| Q3 2024 | $34.0M |
| Q2 2024 | $32.0M |
| Q1 2024 | $21.0M |
| Q4 2023 | $0.0M |
| Q3 2023 | $0.0M |
| Q2 2023 | $0.0M |
| Q1 2023 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| KRAZATI | ADAGRASIB | 200MG | TABLET;ORAL |
1 product